Related Experiment Video
Updated: Jan 23, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
Anna L Beale1,2, Josephine Lillian Warren2, Nia Roberts3
1Heart Failure Research Group, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Insights
Iron deficiency (ID) is common in heart failure with preserved ejection fraction (HFpEF), impacting exercise capacity and quality of life. However, ID did not significantly affect mortality or hospitalizations in patients with HFpEF.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Iron deficiency (ID) significantly impacts outcomes in heart failure with reduced ejection fraction.
- Evidence regarding the prevalence and effects of ID in heart failure with preserved ejection fraction (HFpEF) remains limited.
Conclusions:
- Iron deficiency is highly prevalent in patients diagnosed with HFpEF.
- ID is linked to diminished exercise capacity and functional status in HFpEF.
- Current evidence suggests ID does not significantly influence mortality or hospitalization in this patient population, but warrants further investigation.
Objective:
Iron deficiency (ID) has an established impact on outcomes in patients with heart failure with reduced ejection fraction; however, there is a lack of conclusive evidence in patients with heart failure with preserved ejection fraction (HFpEF). We sought to clarify the prevalence and impact of ID in patients with HFpEF.
Methods:
A systematic search of Cohcrane, MEDLINE, EMBASE, Web of Science and CINAHL electronic databases was performed to identify relevant studies. Included studies defined HFpEF as heart failure with an ejection fraction ≥50%. We used a random-effects meta-analysis to determine the composite prevalence of ID in patients with HFpEF across the included studies. Other outcomes were assessed with qualitative analysis due to a paucity of studies with comparable outcome measures.
Results:
The prevalence of ID in the included studies was 59% (95% CI 52% to 65%). ID was associated with lower VO2 max in three of four studies reporting VO2 max as an outcome measure, lower functional status as determined by dyspnoea class or 6 min walk test in two of three studies, and worse health-related quality of life in both studies reporting on this outcome. Conversely, ID had no impact on death or hospitalisation in three of the four studies investigating this.
Conclusions:
ID is highly prevalent in patients with HFpEF and is associated with worse exercise capacity and functional outcomes, but not hospitalisation or mortality. Our study establishes that ID may play an important a role in HFpEF.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management

